We are live on ! Find out more
ED

Exane Derivatives Portfolio holdings

AUM $174M
1-Year Est. Return 7.84%
This Fund
S&P 500
This Quarter Est. Return
+3.51%
1 Year Est. Return
-7.84%
3 Year Est. Return
+42.72%
5 Year Est. Return
+56.28%
10 Year Est. Return
AUM
$606M
AUM Growth
-$147M
Cap. Flow
-$17.7M
Cap. Flow %
-2.92%
Top 10 Hldgs %
26.18%
Holding
657
New
70
Increased
165
Reduced
211
Closed
108

Sector Composition

Rank Sector Weight
1 Miscellaneous 19.05%
2 Consumer Staples 16.62%
3 Consumer Discretionary 12.86%
4 Financials 10.34%
5 Communication Services 8.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CTIC
651
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
0
SBNY
652
DELISTED
Signature Bank
SBNY
-467
Closed -$63.6K
CELG
653
DELISTED
Celgene Corp
CELG
-2,633
Closed -$264K

Similar funds

Exane Derivatives's Q2 2016 Portfolio in Review

As of Q2 2016, Exane Derivatives held 657 positions worth $606M, down 20% from $753M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Exane Derivatives's Q2 2016 filing shows 70 new, 165 increased, 211 reduced and 108 closed positions. Its largest new stake was UBS Group: 1,623,142 shares worth $20.8M. The largest sale was Applied Materials, an estimated $15.3M.

By sector, the portfolio is most concentrated in Miscellaneous at 19% of assets, down from 34% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Exane Derivatives's largest Q2 2016 buy was UBS Group: 1,623,142 shares worth $20.8M.
  • Exane Derivatives added most to Constellation Brands in Q2 2016, an estimated $12.7M increase.
  • Exane Derivatives's biggest Q2 2016 reduction was Applied Materials, cutting an estimated $15.3M.
  • Exane Derivatives fully exited Masco in Q2 2016, selling an estimated $14.6M.
  • Exane Derivatives's ten largest holdings make up 26% of its $606M portfolio in Q2 2016.
  • Exane Derivatives opened 70 new positions and closed 108 in Q2 2016.
  • Exane Derivatives's portfolio value fell 20% quarter-over-quarter to $606M.

Based on Exane Derivatives's 13F filing for Q2 2016, filed 3 Aug 2016.